Comparative Pharmacology
Head-to-head clinical analysis: MINTEZOL versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINTEZOL versus VANSIL.
MINTEZOL vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category C
Category C
Anthelmintic
Anthelmintic